AsiDNA - Onxeo

Drug Profile

AsiDNA - Onxeo

Alternative Names: AsiDNA™; Dbait; Dbait32H; DNA bait; DNA repair therapeutic - Onxeo; DSB bait; DT-01; DT1

Latest Information Update: 17 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DNA Therapeutics
  • Developer Onxeo SA
  • Class Antineoplastics; DNA
  • Mechanism of Action DNA activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Malignant melanoma
  • Phase I Solid tumours
  • Preclinical Cancer

Most Recent Events

  • 13 Jul 2018 Efficacy data from a preclinical trial in Cancer released by Onxeo
  • 24 Apr 2018 Phase-I clinical trials in Solid tumours (Late-stage disease) in Belgium (IV), Solid tumours (Late-stage disease) in France (IV)
  • 21 Apr 2018 Pharmacodynamics data from a preclinical study in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top